Working… Menu

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04398147
Recruitment Status : Not yet recruiting
First Posted : May 21, 2020
Last Update Posted : July 2, 2020
Beijing Institute of Biotechnology
Canadian Center for Vaccinology
Information provided by (Responsible Party):
CanSino Biologics Inc.

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 20, 2021
Estimated Study Completion Date : December 30, 2021